A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
Latest Information Update: 17 Apr 2024
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Registrational; Therapeutic Use
- Acronyms CASCADE
- Sponsors Swedish Orphan Biovitrum
- 08 Mar 2024 This study has been discontinued in Italy and Austria, according to European Clinical Trials Database record.
- 16 Feb 2024 This study has been discontinued in Norway, according to European Clinical Trials Database record.
- 08 Feb 2024 This study has been discontinued in Hungary and Spain, according to European Clinical Trials Database record.